Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

Hope S. Rugo; Joohyuk Sohn; Yolanda Jerez Gilarranz; Lucia Gonzalez-Cortijo; Amir Sonnenblick; Dhanusha Sabanathan; Ernesto Pablo Korbenfeld; Daniel Egle; Brigitte Poirier; Flora Zagouri; Alexios Matikas; Sercan Aksoy; Umut Demirci; Pier Ramos-Elias; Seock-Ah Im; Fatima Cardoso; Liyi Jia; Carlos Baccan; Konstantinos Tryfonidis; Peter Schmid

Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

Hope S. Rugo
, Joohyuk Sohn
, Yolanda Jerez Gilarranz
, Lucia Gonzalez-Cortijo
, Amir Sonnenblick
, Dhanusha Sabanathan
, Ernesto Pablo Korbenfeld
, Daniel Egle
, Brigitte Poirier
, Flora Zagouri
, Alexios Matikas
, Sercan Aksoy
, Umut Demirci
, Pier Ramos-Elias
, Seock-Ah Im
, Fatima Cardoso
, Liyi Jia
, Carlos Baccan
, Konstantinos Tryfonidis
, Peter Schmid

Division of Internal Medicine (Medicine)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Duration: 3 Jun 2022 → 7 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Rugo, H. S., Sohn, J., Jerez Gilarranz, Y., Gonzalez-Cortijo, L., Sonnenblick, A., Sabanathan, D., Pablo Korbenfeld, E., Egle, D., Poirier, B., Zagouri, F., Matikas, A., Aksoy, S., Demirci, U., Ramos-Elias, P., Im, S.-A., Cardoso, F., Jia, L., Baccan, C., Tryfonidis, K., & Schmid, P. (2022). Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer. Journal of Clinical Oncology, 40(16).

@article{9252be87a133435a815a6b91f168ba6f,

title = "Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer",

author = "Rugo, \{Hope S.\} and Joohyuk Sohn and \{Jerez Gilarranz\}, Yolanda and Lucia Gonzalez-Cortijo and Amir Sonnenblick and Dhanusha Sabanathan and \{Pablo Korbenfeld\}, Ernesto and Daniel Egle and Brigitte Poirier and Flora Zagouri and Alexios Matikas and Sercan Aksoy and Umut Demirci and Pier Ramos-Elias and Seock-Ah Im and Fatima Cardoso and Liyi Jia and Carlos Baccan and Konstantinos Tryfonidis and Peter Schmid",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "16",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 03-06-2022 Through 07-06-2022",

}

Rugo, HS, Sohn, J, Jerez Gilarranz, Y, Gonzalez-Cortijo, L, Sonnenblick, A, Sabanathan, D, Pablo Korbenfeld, E, Egle, D, Poirier, B, Zagouri, F, Matikas, A, Aksoy, S, Demirci, U, Ramos-Elias, P, Im, S-A, Cardoso, F, Jia, L, Baccan, C, Tryfonidis, K & Schmid, P 2022, 'Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer', Journal of Clinical Oncology, vol. 40, no. 16.

Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer. / Rugo, Hope S.; Sohn, Joohyuk; Jerez Gilarranz, Yolanda et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16, 01.06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Keynote-b49

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Rugo, Hope S.

AU - Sohn, Joohyuk

AU - Jerez Gilarranz, Yolanda

AU - Gonzalez-Cortijo, Lucia

AU - Sonnenblick, Amir

AU - Sabanathan, Dhanusha

AU - Pablo Korbenfeld, Ernesto

AU - Egle, Daniel

AU - Poirier, Brigitte

AU - Zagouri, Flora

AU - Matikas, Alexios

AU - Aksoy, Sercan

AU - Demirci, Umut

AU - Ramos-Elias, Pier

AU - Im, Seock-Ah

AU - Cardoso, Fatima

AU - Jia, Liyi

AU - Baccan, Carlos

AU - Tryfonidis, Konstantinos

AU - Schmid, Peter

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000863680304777&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

Y2 - 3 June 2022 through 7 June 2022

ER -

Keynote-b49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

UN SDGs

Other files and links

Cite this